Heron announces fda approval of supplemental new drug application to expand cinvanti® label for iv push national gas average 2007

############

SAN DIEGO, Feb. 26, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug gas calculator Administration (FDA) has approved Heron’s supplemental New Drug Application (sNDA) for CINVANTI electricity in india (aprepitant) injectable emulsion, for intravenous (IV) use. The sNDA requested FDA approval to expand the administration of CINVANTI beyond the already approved administration method (a 30-minute IV infusion) to include a 2-minute IV injection.

CINVANTI is the first and only polysorbate 80-free, IV formulation of an NK 1 receptor antagonist (RA) indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND ® capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK 1 RA to significantly reduce CINV electricity equations physics in both the acute phase (0 – 24 hours after chemotherapy) and the delayed phase (24 – 120 hours after chemotherapy).

CINVANTI was initially approved based on data demonstrating the bioequivalence static electricity review worksheet of CINVANTI to EMEND IV ® (fosaprepitant), supporting its efficacy for the prevention of acute and delayed CINV following highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC). Results from two pivotal, randomized, cross-over, bioequivalence studies of CINVANTI and EMEND IV showed subjects receiving CINVANTI reported fewer adverse events than those receiving gas tax in ct EMEND IV, including substantially fewer infusion-site reactions.

CINVANTI, delivering the efficacy of aprepitant, but without polysorbate 80, has been an important addition for the prevention of CINV. Notably, data now show that the 2-minute IV push has comparable safety to the 30-minute IV infusion. This approval will enable physicians to leverage the operational advantages of this method of administration and will contribute to a reduction in total patient time spent in the infusion suite, said Rudolph M. Navari, M.D., Ph.D., University of Alabama, Birmingham electricity names superheroes School of Medicine, Division of Hematology Oncology.

We are pleased to have strengthened our CINV franchise with today’s label expansion for CINVANTI, as we now have the only NK 1 RA that offers the benefits and flexibility of an IV push method of administration, said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron. Administration of CINVANTI by 2-minute IV push is an important advantage for our customers compared to EMEND IV, which requires reconstitution and an IV bag for infusion.

CINVANTI, in combination z gas guatemala with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC), including high-dose cisplatin, and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). CINVANTI is an IV formulation of aprepitant, a substance P/neurokinin-1 (NK 1) receptor antagonist gas jet size chart (RA). CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND ® capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK 1 RA to significantly reduce nausea and vomiting in both the acute phase (0 – 24 hours after chemotherapy) and the delayed phase (24 – 120 hours after chemotherapy). CINVANTI is the only IV formulation of an NK 1 RA indicated for the prevention of acute astrid y gaston lima reservations and delayed nausea and vomiting associated with HEC and nausea and vomiting associated with gas examples matter MEC that is free of polysorbate 80 or any other synthetic surfactant. The FDA-approved dosing administration included in the United States prescribing information for CINVANTI is a 30-minute infusion or a 2-minute injection.

Serious hypersensitivity reactions, including anaphylaxis during or soon after administration of CINVANTI have occurred. Symptoms including dyspnea, eye swelling, flushing, pruritus, and wheezing have been reported. If hypersensitivity reactions occur, discontinue CINVANTI. Do not reinstate CINVANTI in patients who experience these symptoms with previous use.

Co-administration of CINVANTI with warfarin, a CYP2C9 substrate, may result in a clinically gas 47 cents significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week electricity distribution losses period, particularly at 7 to 10 days, following initiation of CINVANTI with each chemotherapy cycle.

The efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of CINVANTI. Advise patients to use effective alternative or back-up methods of non-hormonal contraception during treatment with CINVANTI and for 1 month following administration of CINVANTI or oral gas constant for nitrogen aprepitant, whichever is administered last.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain v gashi 2012 risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with: the commercial opportunity for CINVANTI IV push z gas ensenada; and other risks and uncertainties identified in the Company’s filings with the U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.